Baidu
map

Hypertension:顽固性高血压增心血管病和终末期肾病风险

2014-08-21 高晓方 译 医学论坛网

美国一项研究表明,显著顽固性高血压(aTRH)可升高心血管疾病和终末期肾病风险。论文8月4日在线发表于《高血压》(Hypertension)。 此项研究从14684例接受降压治疗的受试者中确定了1870例aTRH患者,并评估了aTRH与冠心病、卒中、全因死亡、心衰、外周动脉疾病和终末期肾病的相关性。应用利尿剂并非aTRH所必需。 结果显示,与无aTRH的受试者相比,aTRH患者的冠

美国一项研究表明,显著顽固性高血压(aTRH)可升高心血管疾病和终末期肾病风险。论文8月4日在线发表于《高血压》(Hypertension)。

此项研究从14684例接受降压治疗的受试者中确定了1870例aTRH患者,并评估了aTRH与冠心病、卒中、全因死亡、心衰、外周动脉疾病和终末期肾病的相关性。应用利尿剂并非aTRH所必需。

结果显示,与无aTRH的受试者相比,aTRH患者的冠心病、卒中、全因死亡、心衰、外周动脉疾病和终末期肾病的多变量校正危险比(HR)分别为1.44、1.57、1.30、1.88、1.23和1.95。aTRH与冠心病和心血管疾病综合转归(HR 1.47和1.46)亦有相关性。

原始出处:

Paul Muntner, Barry R. Davis, William C. Cushman, Sripal Bangalore, David A. Calhoun, Sara L. Pressel, Henry R. Black, John B. Kostis, Jeffrey L. Probstfield, Paul K. Whelton, Mahboob Rahman, for the ALLHAT Collaborative Research Group*Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease.Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)HYPERTENSIONAHA.114.03850


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725651, encodeId=9e8e1e2565115, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 11 00:32:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038496, encodeId=7dbb20384966f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 09 02:32:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693423, encodeId=3500169342392, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Aug 23 17:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644418, encodeId=f46f164441871, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jun 13 08:32:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632849, encodeId=beac16328495c, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Sep 13 07:32:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476338, encodeId=d92714e633833, content=<a href='/topic/show?id=eb69e81665d' target=_blank style='color:#2F92EE;'>#终末期肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78166, encryptionId=eb69e81665d, topicName=终末期肾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb27278676, createdName=zengjiayao, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501048, encodeId=9231150104894, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=)]
    2014-09-11 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725651, encodeId=9e8e1e2565115, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 11 00:32:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038496, encodeId=7dbb20384966f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 09 02:32:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693423, encodeId=3500169342392, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Aug 23 17:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644418, encodeId=f46f164441871, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jun 13 08:32:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632849, encodeId=beac16328495c, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Sep 13 07:32:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476338, encodeId=d92714e633833, content=<a href='/topic/show?id=eb69e81665d' target=_blank style='color:#2F92EE;'>#终末期肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78166, encryptionId=eb69e81665d, topicName=终末期肾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb27278676, createdName=zengjiayao, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501048, encodeId=9231150104894, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725651, encodeId=9e8e1e2565115, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 11 00:32:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038496, encodeId=7dbb20384966f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 09 02:32:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693423, encodeId=3500169342392, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Aug 23 17:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644418, encodeId=f46f164441871, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jun 13 08:32:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632849, encodeId=beac16328495c, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Sep 13 07:32:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476338, encodeId=d92714e633833, content=<a href='/topic/show?id=eb69e81665d' target=_blank style='color:#2F92EE;'>#终末期肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78166, encryptionId=eb69e81665d, topicName=终末期肾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb27278676, createdName=zengjiayao, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501048, encodeId=9231150104894, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725651, encodeId=9e8e1e2565115, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 11 00:32:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038496, encodeId=7dbb20384966f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 09 02:32:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693423, encodeId=3500169342392, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Aug 23 17:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644418, encodeId=f46f164441871, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jun 13 08:32:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632849, encodeId=beac16328495c, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Sep 13 07:32:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476338, encodeId=d92714e633833, content=<a href='/topic/show?id=eb69e81665d' target=_blank style='color:#2F92EE;'>#终末期肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78166, encryptionId=eb69e81665d, topicName=终末期肾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb27278676, createdName=zengjiayao, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501048, encodeId=9231150104894, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1725651, encodeId=9e8e1e2565115, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 11 00:32:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038496, encodeId=7dbb20384966f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 09 02:32:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693423, encodeId=3500169342392, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Aug 23 17:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644418, encodeId=f46f164441871, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jun 13 08:32:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632849, encodeId=beac16328495c, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Sep 13 07:32:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476338, encodeId=d92714e633833, content=<a href='/topic/show?id=eb69e81665d' target=_blank style='color:#2F92EE;'>#终末期肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78166, encryptionId=eb69e81665d, topicName=终末期肾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb27278676, createdName=zengjiayao, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501048, encodeId=9231150104894, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1725651, encodeId=9e8e1e2565115, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 11 00:32:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038496, encodeId=7dbb20384966f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 09 02:32:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693423, encodeId=3500169342392, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Aug 23 17:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644418, encodeId=f46f164441871, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jun 13 08:32:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632849, encodeId=beac16328495c, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Sep 13 07:32:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476338, encodeId=d92714e633833, content=<a href='/topic/show?id=eb69e81665d' target=_blank style='color:#2F92EE;'>#终末期肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78166, encryptionId=eb69e81665d, topicName=终末期肾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb27278676, createdName=zengjiayao, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501048, encodeId=9231150104894, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1725651, encodeId=9e8e1e2565115, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 11 00:32:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038496, encodeId=7dbb20384966f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 09 02:32:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693423, encodeId=3500169342392, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Aug 23 17:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644418, encodeId=f46f164441871, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jun 13 08:32:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632849, encodeId=beac16328495c, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Sep 13 07:32:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476338, encodeId=d92714e633833, content=<a href='/topic/show?id=eb69e81665d' target=_blank style='color:#2F92EE;'>#终末期肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78166, encryptionId=eb69e81665d, topicName=终末期肾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb27278676, createdName=zengjiayao, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501048, encodeId=9231150104894, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 23 01:32:00 CST 2014, time=2014-08-23, status=1, ipAttribution=)]

相关资讯

Eur Heart J:强化降脂能显著减少顽固性高血压的主要心血管事件风险(TNT研究)

Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.顽固性高血压患者有更高的心血管不良事件。一般将降低血压作为降低心血管事件的替代终点灭对待。但是强化降脂对这类高风险人群是否有获益,尚不明确。最新一项发表在

ASH 2014:压力感受性反射激活疗法治疗顽固性高血压持续安全有效

Rheos枢纽试验的延长期研究,旨在评估压力感受性反射激活疗法(BAT)治疗顽固性高血压的长期疗效及安全性。 研究者芝加哥大学医学中心的George Bakris 等人在对322例顽固性高血压患者完成为期12个月的随访及终点数据收集后,继续每两年一次收集其血压及安全性数据。为期至少五年的随访结果显示,共计254例(79%)患者对BAT治疗有反应,其血压持续显著降低(P<0.001)。安全性

卢成志:顽固性高血压治疗现状

    高血压病在大多数患者并无特殊症状,因此容易被忽视,但是由其引起的脑卒中、心肌梗死等心脑血管疾病已成为我国的第一杀手,而且高血压还是中风、冠心病、心力衰竭和肾功能衰竭的主要危险因素。《中国高血压指南2010年修订版》、《中国心血管病防治指南》等指南的更新与修改,是根据国内外发表的相关资料,倚重循证医学证据并结合我国实际特点编写的,旨在推进心血管病的防治工作。顽固

Hypertension:顽固性高血压的治疗 药物优于RDN

挪威一项研究表明,在真正顽固性高血压(TRH)患者中,药物调整治疗的降压效果优于去肾交感神经(RDN)治疗。论文3月3日在线发表于《高血压》(Hypertension)。 此项研究共纳入19例TRH患者,并随机给予经导管实施的RDN或临床调整降压药物治疗。以经过包括利尿剂在内的3种最大耐受剂量降压药治疗后,诊室收缩压仍>140 mmHg定义TRH;将降压药监督应用后动态血压恢复正常

ACC 2014:解析SYMPLICITY HTN-3研究结果

     ACC2014会议展示了由美敦力公司发起的SYMPLICITY HTN-3研究的完整结果,研究结果表明肾脏去神经术与假手术对照组相比,降压水平无统计学差异。         SYMPLICITY HTN-3研究是由Bhatt 博士(布莱根妇女医院)和B

沪瑞金经桡动脉肾交感神经消融治顽固高血压

由瑞金医院高血压科高平进教授和心脏科张瑞岩教授领衔的团队于11月14日在瑞金医院心导管室完成了国内首例经桡动脉肾交感神经消融治疗顽固性高血压,取得完满成功。 鉴于众多临床研究的良好结果,肾交感神经消融已成为国外目前治疗顽固性高血压的重要手段。但该领域在国内仍处于刚刚起步阶段,上海瑞金医院与北京阜外医院共同率先在国内开展了该领域的临床研究。 经过严格的患者筛选,上海瑞金医院高血压科和心脏内科团队

Baidu
map
Baidu
map
Baidu
map